Diagnostics Industry

Found 4,017 articles

• Todos Medical Announces All 31 Patients Enrolled to Date in Tollovir® Phase 2 Clinical Trial in Hospitalized COVID-19 Patients Have Completed Study Participation

  12/2/2021

  Todos Medical, Ltd., a comprehensive medical diagnostics and related solutions company, together with its 3CL biology-focused joint venture partner NLC Pharma, announced that all 31 patients enrolled to date in Tollovir® Phase 2 clinical trial in hospitalized COVID-19 patients have completed study participation and the data are now being entered into the database for analysis.

• PAVmed Subsidiary Lucid Diagnostics Launches EsoGuard Telemedicine Program in Partnership with UpScriptHealth

  12/1/2021

  Lucid Diagnostics Inc. a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc., announced it has launched its EsoGuard Telemedicine Program in partnership with UpScriptHealth, a leading, nationwide, direct-to-consumer telemedicine company.

• Clinical Data of The Visby Medical Sexual Health Click Test Published in Journal of the American Sexually Transmitted Diseases Association

  12/1/2021

  Visby Medical, a leading medical diagnostic company, announced results from the cross-sectional single visit patient outcomes and implementation study, which evaluated self-collected vaginal swab samples from 55 women using the Visby Medical Sexual Health Click Test for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis.

• Yokogawa Develops Single Cellome System SS2000 for Subcellular Sampling

  12/1/2021

  Yokogawa Electric Corporation announces that it has developed the Single Cellome™ System SS2000, a single-cell analysis solution that utilizes high-resolution images captured with a confocal microscope to automatically and accurately collect samples of specific cells and intracellular components.

• Q2 Interim Report - Promising Results Published at ESMO

  12/1/2021

  Biovica has strengthened its management team with the addition of Warren Cresswell, President Americas, with responsibility for the launch of DiviTum®TKa in the USA.

• Todos Medical to Host Business Update Conference Call on December 2nd at 4:30 PM EST

  12/1/2021

  Todos Medical, Ltd. announced that the management team of Todos Medical, including Mr. Gerald E. Commissiong, President and Chief Executive Officer, will host a conference call on Thursday, December 2nd at 4:30 p.m. EST to discuss the Company’s business progress in 2021 and provide a strategic outlook for the future.

• DiaCarta's Multivariant COVID-19 Test Accurately Detects the Omicron Variant

  11/30/2021

  DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy announced today that the company has developed a novel test to detect the newest COVID-19 Omicron variant, based on its proprietary XNA technology.

• FDA Clears SeptiCyte® RAPID - The First One-Hour, Direct-from-Blood Sepsis Test

  11/30/2021

  Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced that SeptiCyte® RAPID has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

• StatLab Announces Appointment of Kim Kelderman to its Board of Directors

  11/30/2021

  StatLab Medical Products (StatLab), a leading developer and manufacturer of diagnostic supplies and equipment for the anatomic pathology market, today announced the appointment of industry veteran Kim Kelderman to the StatLab Board of Directors.

• Todos Medical Confirms SARS-CoV-2 PCR Test Kits Used at CLIA/CAP Lab Provista Diagnostics Detect Omicron Variant

  11/30/2021

  Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced it has confirmed with its PCR test kit providers that the PCR test kits utilized at its CLIA/CAP certified lab Provista Diagnostics based in the Atlanta, GA area are able to detect a SARS-CoV-2 infection caused by the Omicron variant, as well as all other variants of concern, based on in silico analysis.

• Seegene's High Multiplex PCR Assay Capable of Detecting New Omicron Variant

  11/30/2021

  Seegene Inc., South Korea's leading molecular diagnostics company, confirmed that its Allplex™ SARS-CoV-2 Master Assay is capable of detecting the Omicron's unique pattern of mutations.

• Quidel Statement on the Omicron Variant

  11/30/2021

  Quidel Corporation issued the following statement from Douglas Bryant, Quidel’s President and CEO, regarding Quidel’s ongoing efforts to evaluate COVID-19 mutations and confirm that its American-made PCR and antigen tests continue to detect COVID-19 variants such as Omicron.

• Blue Earth Diagnostics Highlights Axumin® (Fluciclovine F 18) Presentation at Upcoming 22nd Annual Scientific Meeting in Urologic Oncology (SUO)

  11/30/2021

  Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, announced a presentation on Axumin® at the upcoming 22nd Annual Scientific Meeting in Urologic Oncology, to be held in Orlando, Fla., from December 1 to 3, 2021.

• Biofrontera Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update

  11/30/2021

  Biofrontera Inc., a biopharmaceutical company specializing in the commercialization of dermatological products, announced financial results for the three and nine months ended September 30, 2021.

• Mainz Biomed Establishes Partnership with Precision for Medicine to Support ColoAlert’s U.S. Regulatory and Commercial Strategy

  11/30/2021

  Mainz Biomed N.V. announced the Company has engaged Precision for Medicine, a leading global Clinical Research Organization, to provide U.S. regulatory and reimbursement advisory support for ColoAlert, Mainz’s highly efficacious and easy-to-use diagnostic test for colorectal cancer.

• Cue Health Confirms COVID-19 Tests Can Detect Omicron Variant

  11/29/2021

  Cue Health ("Cue") (Nasdaq: HLTH), a healthcare technology company, today announced it has completed an analysis of the SARS-CoV-2 B.1.1.529 variant, designated by the World Health Organization as Omicron.

• QIAGEN and DiaSorin widen access to latent TB testing in the U.S. with FDA approval of QuantiFERON®-TB Gold Plus assay on LIAISON® XS

  11/29/2021

  QIAGEN and DiaSorin announced that the U.S. Food and Drug Administration has approved the LIAISON® QuantiFERON®-TB Gold Plus assay for use on DiaSorin’s automated LIAISON® XS platform.

• Co-Diagnostics, Inc. Reports that Suite of COVID-19 Diagnostics Not Affected by Heavily Mutated Omicron Variant

  11/29/2021

  Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), reported today that none of the mutations in the heavily mutated SARS-CoV-2 variant recently discovered in Africa are predicted to interfere with any of the Company's suite of COVID-19 PCR diagnostic assays.

• SphingoTec Appoints Jörg Menten to Leadership Team as Chief Commercial Officer to Drive New Business Growth

  11/29/2021

  Diagnostics company SphingoTec GmbH announced the appointment of Jörg Menten as its Chief Commercial Officer.

• Biofrontera Inc. Pricing of $15 Million Private Placement Priced At-the-Market Under Nasdaq Rules

  11/29/2021

  Biofrontera, Inc., announced today that it has entered into a securities purchase agreement with a single institutional investor for the purchase of 2,857,143 shares of its common stock and warrants to purchase up to an aggregate of 2,857,143 shares of common stock, in a private placement.